1. Introduction {#sec1}
===============

Due to its prevalence rates exceeding 50% among individuals aged 65-80 years and reaching 80% above the age of 80, olfaction dysfunction is considered a very common problem in older populations \[[@B1]\]. This sensory deficit has important implications for safety, nutrition, quality of life, and social relationships \[[@B2]\]. Olfactory impairment is partially age-related and reflects either central neurodegenerative mechanisms or peripheral cumulative damage of olfactory receptors \[[@B1]\]. In fact, the olfactory system is the only sense which depends upon stem cell turnover, and the olfactory nerve is the only cranial nerve directly exposed to the environment \[[@B1]\].

Frailty is an age-related condition of increased vulnerability, associated with higher risk of several adverse outcomes, including mortality \[[@B3]\]. Among different criteria proposed to define frailty, the frailty phenotype proposed by Fried and colleagues is among the most commonly adopted \[[@B4]\]; also, prefrailty status has been associated with reduced survival, as compared with robustness \[[@B3]\]. Indeed, frailty can be attenuated and even reversed, so that this syndrome has to be considered a dynamic process, mainly for subjects in their intermediate stage \[[@B5]\]. In an Italian cohort of elderly people, although most participants tended to retain their baseline frailty status, more than one-third of the sample experienced a transition (with either improvement or worsening) in their frailty status over a four-year follow-up \[[@B6]\].

It has been documented that sensory perception, including smell perception, is associated with several components of frailty \[[@B7]\]. On the other hand, it has been acknowledged that both frailty and olfactory loss are associated with reduced survival \[[@B3], [@B8]\]. Furthermore, both olfactory impairment and frailty are characterized by subclinical inflammation, which could partially explain the adverse outcomes associated with these two conditions.

Olfactory impairment, but not hearing or visual impairment, has been associated with decreased survival in older subjects \[[@B9]\]. However, to our knowledge, neither the association of olfactory impairment with prefrailty nor the impact of frailty phenotypes on the association between olfactory dysfunction and mortality has been so far investigated.

The aim of this study was to assess in an older population the association, if any, of olfactory dysfunction with frailty and mortality and whether such an association might be mediated by frailty status.

2. Methods {#sec2}
==========

2.1. Study Design and Participants {#sec2.1}
----------------------------------

The present study is based upon the data from the "Invecchiare in Chianti" study, a prospective population-based study of older persons in Tuscany, Italy, that is aimed at identifying risk factors for late-life disability \[[@B10]\]. The Italian National Research Council on Aging Ethical Committee ratified the study protocol, and participants provided written consent to participate.

Analyses for this study included all 1035 subjects aged 65+.

2.2. Frailty {#sec2.2}
------------

Frailty was defined according to the Fried criteria \[[@B4]\]: unintended weight loss, self-reported exhaustion, muscle weakness, slowness, and sedentariness. Weight loss was defined as self-reported unintentional weight loss \> 4.5 kg within the past year. Exhaustion was defined as a response of "occasionally," "often," or "always" to the statement "I felt that everything was an effort." Muscle weakness was defined as grip strength in the lowest quintile, stratified by sex and BMI quartiles. Grip strength was measured by a handheld dynamometer (Nicholas Muscle Tester, Sammons Preston Inc.). Slowness was defined as the time to walk 4.57 meters or 15 ft (the mean of 2 repetitions) in the slowest quintile, stratified by sex and height. Sedentariness was defined as either complete inactivity or spending \<1 h/wk performing low-intensity activities. "Frailty" was defined as the presence of at least three criteria, "prefrailty" of one or two criteria, and "robustness" of none.

This syndrome is thought to emerge from multisystem dysregulation that is common in older adults and characterized by increased vulnerability to stressors and increased risk of disease, disability, and death. Also, frailty is linked to multimorbidity and inflammation.

2.3. Mortality {#sec2.3}
--------------

Data on 9-year mortality were collected using the data from the Mortality General Registry maintained by the Tuscany Region, as well as death certificates delivered immediately after death to the registry office of the municipality of residence.

2.4. Olfactory Function {#sec2.4}
-----------------------

Olfactory function was self-reported and explored during the medical visit according to the questions: "Does he/she recognize mint?", "does he/she recognize coffee?", and "does he/she recognize air?". Olfactory dysfunction was defined when at least two smells were not recognized. Increasing levels of olfactory impairment (0 to 3 smell losses) were also considered.

2.5. Inflammation {#sec2.5}
-----------------

Blood samples were drawn in the morning after a 12-hour overnight fast and resting period. Aliquots of serum were stored at −80°C. Serum interleukin-6 (IL-6) was measured in duplicate by high-sensitivity enzyme-linked immunosorbent assays (ELISAs; kits from BioSource, Camarillo, CA) with a sensitivity of 0.1 pg/mL and an intra-assay coefficient of variations less than 6%.

2.6. Covariates {#sec2.6}
---------------

Data on dietary intake were collected by the questionnaire created for the European Prospective Investigation into Cancer and Nutrition (EPIC) study \[[@B11]\]. Adjudicated disease diagnoses were based on self-reported history, clinical documentation, and medication use, as well as standardized criteria derived from the Women\'s Health and Aging Study protocol \[[@B12]\]. Comorbidity was quantified using the Charlson Comorbidity Index score \[[@B13]\]. All drugs assumed by participants were coded according to the Anatomical Therapeutic Chemical codes \[[@B14]\]. Functional ability was estimated using Katz\'s activities of daily living \[[@B15]\], depressive symptoms by the original 20-item version of the Center for Epidemiological Studies Depression Scale (CES-D) \[[@B16]\], and cognitive performance by the Mini Mental State Examination \[[@B17]\]. Blood samples were obtained from participants after 12-hour fasting and after resting for at least 15 minutes. Aliquots of serum were stored at --80°C and were not thawed until analysis. Interleukin-6 concentrations were determined by high-sensitivity ELISA using commercial kits (Human Ultrasensitive, BioSource International Inc., Camarillo, CA, USA). Glomerular filtration rate was estimated using the Cockcroft-Gault equation.

2.7. Statistical Analyses {#sec2.7}
-------------------------

Data were recorded using dedicated software. Statistical analyses were performed using Statistical Package for the Social Sciences (SPSS for Mac version 20.0, 2011, SPSS Inc., Chicago, IL); differences were considered significant at the *P* \< .050 level.

Data of continuous variables are presented as mean values ± standard deviation or medians and interquartile ranges. Normally distributed variables according to olfactory dysfunction, as well as to mortality, were assessed by the analysis of variance (ANOVA) or the nonparametric Mann--Whitney *U* test if appropriate. The two-tailed Fisher exact test was used for dichotomous variables.

Multivariable logistic regression was used to evaluate the association of the frailty phenotype with age, sex, and all those variables which differed significantly in univariate analysis, including olfactory dysfunction.

The fully adjusted model was also adopted to evaluate the association of increasing levels of olfactory dysfunction with frailty. Also, the analysis of the interaction terms "olfactory dysfunction^∗^interleukin-6" was performed to assess whether the association of frailty with olfactory dysfunction varied according to inflammation.

In addition, to evaluate the whole spectrum of the frailty phenotype, the same summary model was analysed in multinomial logistic regression having robustness, prefrailty, and frailty as the dependent variables.

Also, Cox proportional hazard regression analysis was used to estimate the association of mortality with age, sex, and all those variables which differed significantly in univariate analysis, including olfactory dysfunction. Eventually, in Cox regression, the analysis of the interaction terms "olfactory dysfunction^∗^frailty," "olfactory dysfunction^∗^prefrailty," and "olfactory dysfunction^∗^interleukin-6," was performed to assess whether the association between reduced survival and olfactory dysfunction varied according to the presence of frailty, prefrailty, and inflammatory status.

3. Results {#sec3}
==========

The main characteristics of 1035 participants according to olfactory dysfunction are depicted in [Table 1](#tab1){ref-type="table"}. Frailty was diagnosed in 111 (11%) subjects, prefrailty in 420 (41%) participants, and robustness in 504 (48%). The main characteristics of subjects according to frailty are shown in [Table 2](#tab2){ref-type="table"}.

Over the 9-year follow-up, 393 (38%) subjects died. The main characteristics of participants according to survival are depicted in [Table 3](#tab3){ref-type="table"}.

Olfactory dysfunction was reported by 590/1035 (57%) participants; specifically, lack of recognition of one smell was recorded in 190 (18%) subjects, two smells in 243 (23%), and three smells in 347 (33%). In particular, failure to recognize air was found in 638 (62%) subjects, failure to recognize mint was found in 574 (55%), and failure to recognize coffee was found in 505 (49%).

In multivariable logistic regression, olfactory dysfunction was associated with increased probability of being frail (OR 1.94, 95% CI = 1.07-3.51; *P* = .028), after adjusting ([Table 4](#tab4){ref-type="table"}). Analysis of the interaction term indicated that the association of frailty with olfactory dysfunction varied according to interleukin-6 levels (*P* for interaction = .005).

Also, increasing levels of olfactory dysfunction were associated with increasing probability of frailty (*P* for trend = .021).

Both frailty (OR 2.60, 95% CI = 1.39-4.85) and prefrailty (OR 1.59, 95% CI = 1.17-2.16) were associated with olfactory dysfunction in multinomial logistic having robustness as the reference.

According to Cox regression analysis, olfactory dysfunction was associated with reduced survival (HR 1.52, 95% CI = 1.16-1.98; *P* = .002), after adjusting ([Figure 1](#fig1){ref-type="fig"}); analysis of the interaction term indicated that this association varied according to the presence of frailty (*P* = .017), prefrailty (*P* = .046), and increased interleukin-6 levels (*P* for interaction = .011).

4. Discussion {#sec4}
=============

Results of the present study indicate that in older subjects, olfactory dysfunction is associated not only with frailty, but even with prefrailty. This association seems to be mediated by subclinical inflammation.

This association was independent of several confounders, including comorbid conditions, medication use, and lifestyle habits; this finding indicates that olfactory dysfunction might represent an early marker of increased risk for adverse outcomes. In fact, in this population, olfactory dysfunction represented a risk factor for reduced survival, and both frailty and prefrailty seemed to mediate this association.

Several factors might explain the association of olfactory dysfunction with frailty and mortality.

Olfactory dysfunction is among the earliest findings which predict the development of mild cognitive impairment \[[@B18]\]. Also, olfactory dysfunction heralds several neurodegenerative disorders, including Parkinson\'s disease, which is a paradigm of frailty \[[@B2]\]; of notice, olfactory loss has been included as a marker of prodromal Parkinson\'s disease by the Movement Disorders Society \[[@B19]\]. Among patients with Parkinson\'s disease, the severity of olfactory dysfunction seems to correlate with the severity of ensuing dementia \[[@B2]\].

In experimental as well as human models, olfactory dysfunction has been linked with the expression of the apolipoprotein e4 allele and of tau protein and amyloid-*β* deposits \[[@B20], [@B21]\]; all these findings, in turn, are associated with several adverse clinical outcomes, including cardiovascular diseases and Alzheimer\'s disease \[[@B20]\]. Olfactory dysfunction has also been associated with depression, probably due to the damage of the hippocampal pathways \[[@B22]\]. In turn, late-life depression has been associated with increased risk of dementia \[[@B23]\].

Systemic diseases, such as diabetes, iron deficiency, and autoimmune diseases, might cause central and peripheral olfactory dysfunction and disrupt the peripheral olfactory pathways \[[@B24], [@B25]\]. The olfactory deficit represents a preclinical marker of alpha-synucleinopathies and a risk factor for delirium \[[@B2], [@B26]\]. Also, impairment in olfactory function has been related to the intake of macro- and micronutrients and directly affects food intake behaviour \[[@B27]\]. Eventually, olfactory dysfunction represents a risk factor for reduced survival \[[@B8]\]. Even better, olfactory dysfunction is the only sense which has been associated with mortality, when compared with hearing or visual impairment \[[@B9]\]. With special regard to the frailty components, olfactory function is associated with mobility, balance, fine motor function, and manual dexterity and independent of cognitive function, with challenging upper- and lower-extremity motor function tasks \[[@B28]\]. Also, olfactory loss represents a risk factor for weight loss, while aerobic exercise might preserve olfactory function in selected populations, such as patients with Parkinson\'s disease \[[@B2], [@B29]\].

Furthermore, our finding of a potential role of IL-6 serum levels in the association between olfactory loss and frailty is of interest. Increased IL-6 levels have been found in serum and nasal mucus of hyposmic patients \[[@B30]\]. On the other hand, increased IL-6 serum levels have also been associated with frailty, as well as mortality, in older populations \[[@B31], [@B32]\]. Thus, inflammation represents a common pathophysiological pathway that links hyposmia, frailty, and mortality in the elderly.

In this study, olfactory dysfunction was self-assessed. Self-assessed tools for evaluating olfactory function might underestimate the dysfunction, as compared with objective evaluation. Nevertheless, this would represent a conservative bias, which further supports our findings. Also, regarding the association of olfactory dysfunction with frailty, due to its cross-sectional design, this study does not allow establishing any cause-effect relationship. Nonetheless, this study enrolled a representative community-dwelling population, with high participation rate and with extensive information on risk factors, comorbid conditions, and objective parameters.

In conclusion, olfactory loss represents a correlate of frailty and even of prefrailty; this association seems to affect the role of olfactory dysfunction as a predictor of mortality in older populations. Thus, olfaction seems worth testing in geriatric practice for both clinical and epidemiological purposes.

The InCHIANTI study baseline (1998--2000) was supported as a targeted project (ICS110.1/RF97.71) by the Italian Ministry of Health and in part by the U.S. National Institute on Aging (Contracts 263 MD 9164 and 263 MD 821336); the InCHIANTI Follow-Up 1 (2001--2003) was funded by the U.S. National Institute on Aging (Contracts N.1-AG-1-1 and N.1-AG-1-2111), Baltimore, Maryland.
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###### 

Characteristics of 1035 participants according to olfactory dysfunction.

                                                                        Presence of olfactory dysfunction (*n* = 590)   Absence of olfactory dysfunction (*n* = 445)   *P*
  --------------------------------------------------------------------- ----------------------------------------------- ---------------------------------------------- --------
  *Demographics & lifestyle habits,n(%), mean (SD), or median (IQR)*                                                                                                   
  Age (years)                                                           76 (8)                                          73 (7)                                         \<.001
  Sex (female)                                                          315 (53)                                        262 (59)                                       .088
  Education (years)                                                     5 (3)                                           6 (3)                                          .003
  Living alone                                                          241 (41)                                        164 (37)                                       .199
  Smoking (former and current)                                          253 (43)                                        170 (38)                                       .142
  *Dietary intake*                                                                                                                                                     
  Alcohol (g/day/kg)                                                    0.11 (0--0.29)                                  0.10 (0--0.31)                                 .594
  Total protein intake (g/day/kg)                                       1.12 (0.33)                                     1.13 (0.31)                                    .657
  Total lipid intake (g/day/kg)                                         0.96 (0.31)                                     0.98 (0.31)                                    .310
  Available carbohydrate intake (g/day/kg)                              3.73 (1.17)                                     3.72 (1.29)                                    .913
  Fibre (g/day/kg)                                                      0.29 (0.08)                                     0.29 (0.08)                                    .551
  Energy intake (kcal/day/kg)                                           28.60 (8.25)                                    28.71 (8.50)                                   .829
  *Comorbid conditions,n(%) or median (IQR)*                                                                                                                           
  Diabetes                                                              67 (11)                                         47 (11)                                        .764
  Heart failure                                                         39 (7)                                          20 (4)                                         .176
  Chronic pulmonary disease                                             52 (9)                                          37 (8)                                         .823
  Parkinson\'s disease                                                  15 (2)                                          12 (3)                                         .999
  Stroke                                                                37 (6)                                          23 (5)                                         .503
  Hip fracture                                                          19 (3)                                          19 (4)                                         .406
  Peripheral arterial disease                                           80 (14)                                         41 (9)                                         .032
  Malignancy                                                            28 (5)                                          36 (8)                                         .036
  Frailty phenotype                                                     85 (14)                                         26 (6)                                         \<.001
  Charlson Comorbidity Index                                            1 (0-2)                                         1 (0-1)                                        .489
  *Medications,n(%), mean (SD), or median (IQR)*                                                                                                                       
  Neuroleptics                                                          18 (3)                                          15 (3)                                         .859
  Selective serotonin reuptake inhibitors                               13 (2)                                          3 (1)                                          .072
  ACE inhibitors                                                        92 (16)                                         49 (11)                                        .035
  Antiplatelets                                                         73 (12)                                         40 (9)                                         .088
  Anticoagulants                                                        8 (1)                                           5 (1)                                          .787
  Benzodiazepines                                                       112 (19)                                        61 (14)                                        .029
  Loop diuretics                                                        53 (9)                                          32 (7)                                         .306
  Corticosteroids                                                       8 (1)                                           10 (2)                                         .339
  *Biohumoral, physical, and cognitive parameters,n(%) ormean* ± *SD*                                                                                                  
  Glomerular filtration rate (mL/min)                                   62.6 (19.3)                                     68.1 (19.2)                                    \<.001
  Total serum proteins (g/dL)                                           7.2 (0.4)                                       7.1 (0.5)                                      .308
  Interleukin 6 (pg/mL)                                                 1.49 (0.84-2.32)                                1.44 (0.88-2.27)                               .582
  Hemoglobin (g/dL)                                                     13.6 (1.4)                                      13.8 (1.4)                                     .112
  CES-D                                                                 13 (9)                                          12 (8)                                         .035
  Mini Mental State Examination                                         24.3 (4.3)                                      24.7 (5.5)                                     .160
  Katz\'s activities of daily living                                    5 (1)                                           4 (2)                                          .107
  Body mass index (kg/m^2^)                                             27.3 (4.0)                                      27.6 (4.2)                                     .183

###### 

Characteristics of 1035 participants according to the presence of frailty.

                                                                        Positive for frailty (*n* = 111)   Negative for frailty (*n* = 924)   *P*
  --------------------------------------------------------------------- ---------------------------------- ---------------------------------- --------
  *Demographics & lifestyle habits,n(%), mean (SD), or median (IQR)*                                                                          
  Age (years)                                                           81 (7)                             74 (7)                             \<.001
  Sex (female)                                                          70 (63)                            507 (55)                           .106
  Education (years)                                                     4 (3)                              5 (3)                              \<.001
  Living alone                                                          68 (61)                            337 (36)                           \<.001
  Smoking (former and current)                                          38 (34)                            385 (42)                           .153
  *Dietary intake*                                                                                                                            
  Alcohol (g/day/kg)                                                    0.04 (0--0.25)                     0.11 (0--0.31)                     .021
  Total protein intake (g/day/kg)                                       1.04 (0.30)                        1.12 (0.32)                        .009
  Total lipid intake (g/day/kg)                                         0.87 (0.28)                        0.97 (0.31)                        .002
  Available carbohydrates intake (g/day/kg)                             3.41 (1.11)                        3.76 (1.23)                        .008
  Fibre (g/day/kg)                                                      0.27 (0.09)                        0.30 (0.09)                        .006
  Energy intake (kcal/day/kg)                                           26.0 (7.5)                         29.0 (8.4)                         .001
  *Comorbid conditions,n(%) or median (IQR)*                                                                                                  
  Diabetes                                                              16 (14)                            98 (11)                            .259
  Heart failure                                                         19 (17)                            40 (4)                             \<.001
  Chronic pulmonary disease                                             18 (16)                            71 (8)                             .006
  Parkinson\'s disease                                                  8 (7)                              19 (2)                             .002
  Stroke                                                                16 (14)                            44 (5)                             \<.001
  Hip fracture                                                          11 (10)                            27 (3)                             .001
  Peripheral arterial disease                                           23 (21)                            98 (11)                            .004
  Malignancy                                                            8 (7)                              56 (6)                             .675
  Olfactory dysfunction                                                 85 (77)                            505 (55)                           \<.001
  Charlson Comorbidity Index                                            1 (1-2)                            0 (0-1)                            \<.001
  *Medications,n(%), mean (SD), or median (IQR)*                                                                                              
  Neuroleptics                                                          10 (9)                             23 (5)                             .001
  Selective serotonin reuptake inhibitors                               7 (6)                              9 (1)                              .001
  ACE inhibitors                                                        24 (22)                            117 (13)                           .013
  Antiplatelets                                                         18 (16)                            95 (10)                            .075
  Anticoagulants                                                        2 (2)                              11 (1)                             .641
  Benzodiazepines                                                       32 (29)                            141 (15)                           .001
  Loop diuretics                                                        21 (19)                            64 (7)                             \<.001
  Corticosteroids                                                       4 (4)                              14 (1)                             .118
  *Biohumoral, physical, and cognitive parameters,n(%) ormean* ± *SD*                                                                         
  Glomerular filtration rate (mL/min)                                   54.8 (20.5)                        66.0 (19.0)                        \<.001
  Total serum proteins (g/dL)                                           7.2 (0.6)                          7.1 (0.4)                          .838
  Interleukin 6 (pg/mL)                                                 2.21 (1.35 -- 4.09)                1.40 (0.83--2.07)                  \<.001
  Hemoglobin (g/dL)                                                     13.1 (1.6)                         13.8 (1.3)                         \<.001
  CES-D                                                                 20 (9)                             12 (8)                             \<.001
  Mini Mental State Examination                                         21 (6)                             25 (4)                             \<.001
  Katz\'s activities of daily living                                    6 (0-1)                            6 (0--0)                           \<.001
  Body mass index (kg/m^2^)                                             27.9 (5.1)                         27.4 (4.0)                         .289

###### 

Characteristics of 1035 participants according to survival status.

                                                                        Dead (*n* = 393)    Alive (*n* = 642)   *P*
  --------------------------------------------------------------------- ------------------- ------------------- --------
  *Demographics & lifestyle habits,n(%), mean (SD), or median (IQR)*                                            
  Age (years)                                                           80 (7)              72 (5)              \<.001
  Sex (female)                                                          200 (51)            377 (59)            .014
  Education (years)                                                     5 (3)               6 (3)               \<.001
  Living alone                                                          206 (52)            199 (31)            \<.001
  Smoking (former and current)                                          172 (44)            251 (39)            .152
  *Dietary intake*                                                                                              
  Alcohol (g/day/kg)                                                    0.10 (0--0.26)      0.10 (0--0.32)      .021
  Total protein intake (g/day/kg)                                       1.14 (0.32)         1.11 (0.32)         .262
  Total lipid intake (g/day/kg)                                         0.97 (0.30)         0.96 (0.32)         .582
  Available carbohydrate intake (g/day/kg)                              3.82 (1.26)         3.67 (1.20)         .066
  Fibre (g/day/kg)                                                      0.29 (0.09)         0.29 (0.08)         .654
  Energy intake (kcal/day/kg)                                           29.08 (8.33)        28.40 (8.37)        .227
  *Comorbid conditions,n(%) or median (IQR)*                                                                    
  Diabetes                                                              52 (13)             62 (10)             .082
  Heart failure                                                         46 (12)             13 (2)              \<.001
  Chronic pulmonary disease                                             63 (16)             26 (4)              \<.001
  Parkinson\'s disease                                                  21 (5)              6 (1)               \<.001
  Stroke                                                                44 (11)             16 (2)              \<.001
  Hip fracture                                                          24 (6)              14 (2)              .002
  Peripheral arterial disease                                           86 (22)             35 (5)              \<.001
  Malignancy                                                            28 (7)              36 (6)              .353
  Olfactory dysfunction                                                 249 (63)            341 (53)            .001
  Frailty                                                               90 (23)             21 (3)              \<.001
  Charlson Comorbidity index                                            1 (0-2)             0 (0-1)             \<.001
  *Medications,n(%), mean (SD), or median (IQR)*                                                                
  Neuroleptics                                                          17 (4)              16 (2)              .143
  Selective serotonin reuptake inhibitors                               11 (3)              5 (1)               .017
  ACE inhibitors                                                        72 (18)             69 (11)             .001
  Antiplatelets                                                         65 (16)             48 (7)              \<.001
  Anticoagulants                                                        11 (3)              2 (1)               .001
  Benzodiazepines                                                       81 (21)             92 (14)             .010
  Loop diuretics                                                        55 (14)             30 (5)              \<.001
  Corticosteroids                                                       11 (3)              7 (1)               .050
  *Biohumoral, physical, and cognitive parameters,n(%) ormean* ± *SD*                                           
  Glomerular filtration rate (mL/min)                                   56.4 (19.5)         69.5 (17.8)         \<.001
  Total serum proteins (g/dL)                                           7.1 (0.5)           7.1 (0.4)           .680
  Interleukin 6 (pg/mL)                                                 1.89 (1.14--3.31)   1.22 (0.78--1.84)   \<.001
  Hemoglobin (g/dL)                                                     13.4 (1.6)          13.9 (1.2)          \<.001
  CES-D                                                                 14 (9)              12 (9)              \<.001
  Mini Mental State Examination                                         22 (6)              26 (3)              \<.001
  Katz\'s activities of daily living                                    5 (1)               6 (0)               \<.001
  Body mass index (kg/m^2^)                                             27.0 (4.3)          27.7 (4.0)          .016

###### 

Association (odds ratios (OR) and 95% confidence intervals (CI)) of frailty with the variables of interest, including olfactory dysfunction, according to the logistic regression model. All the covariates were entered simultaneously into the regression model.

                                        OR     95% CI      *P*
  ------------------------------------- ------ ----------- --------
  Age (each year)                       1.15   1.09-1.21   \<.001
  Sex (female)                          .92    .52-1.64    .778
  Education (years)                     .95    .86-1.05    .306
  Malignancy                            1.72   .65-4.57    .279
  Peripheral arterial disease           2.46   1.29-4.69   .006
  ACE inhibitors                        1.65   .87-3.12    .122
  Benzodiazepines                       1.15   .63-2.10    .653
  Glomerular filtration rate (mL/min)   1.02   1.01-1.04   .018
  CES-D                                 1.11   1.07-1.14   .000
  Olfactory dysfunction                 1.94   1.07-3.51   .028
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